|Home||About us||Molecular assays||Partnerships & licensing||Investor room||News|
QIAGEN Marseille develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path.
With more than 60 tests used routinely worldwide for diagnosis, prognosis and follow-up of thousands of patients with blood cancer, QIAGEN Marseille is also developping diagnostic tools targeting other cancers. Its goal is to provide information, remaining unavailable until now, to sustain the development of personalized medicine.
Founded as IPSOGEN in 1999, the company is, since July 2011, a subsidiary of the QIAGEN group, the leading global provider of sample and assay technologies. From January 1st 2013, IPSOGEN has changed its Company name to QIAGEN Marseille. The company, located in Marseille, France, employed 75 people as of December 31, 2013.
Within the QIAGEN Group, Marseille serves as a Center of Excellence:
QIAGEN Marseille SA
Luminy Biotech Entreprises, Case 923, 163 avenue de Luminy | 13288 Marseille - Cedex 9 | FRANCE
Office:+33 (0) 491 29 30 90 | Fax:+33 (0) 491 29 30 99| Email
74 employees as of December 31, 2012
89 patents and pending patents (19 patent families)
More than 80 references
More than 400 active clients in 61 countries
QIAGEN N.V.: 89.30%
Other shareholders: 10.70%